MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
复制标题
DOI：
10.1001/jama.299.4.425
复制
发表时间：
2008-01-30
影响因子：
120.7
通讯作者：
Harris, Curtis C.
中科院分区：
文献类型：
--
作者：
Schetter, Aaron J.;Leung, Suet Yi;Harris, Curtis C.
背景MicroRNA具有作为癌症诊断生物标志物和治疗靶点的潜力。没有研究评估microRNA表达模式与结肠癌预后或治疗结果之间的关联。目的鉴定与结肠腺癌、预后或治疗结果相关的microRNA表达模式。设计、设置和患者对84例结肠腺癌患者的US测试队列进行肿瘤和配对非肿瘤组织的microRNA微阵列表达谱分析，在1993年至2002年期间招募。我们评估了肿瘤状态、TNM分期、生存预后和辅助化疗反应的相关性。在1991年至2000年招募的113名患者的第二个独立的中国队列中，使用定量逆转录聚合酶链反应分析验证了相关性。随访的最后日期为2005年12月31日，对于马里兰州队列和2004年8月16日，对于香港队列.Main Outcome Measures microRNA在肿瘤中的差异表达和microRNA表达模式与使用癌症特异性死亡作为终点的存活率相关.Results 37个microRNA在来自测试队列的肿瘤中差异表达。选择用于验证的是miR-20 a、miR- 21、miR-106 a、miR-181 b和miR- 203，并且所有5种都在来自验证队列的肿瘤中富集（P
Context MicroRNAs have potential as diagnostic biomarkers and therapeutic targets in cancer. No study has evaluated the association between microRNA expression patterns and colon cancer prognosis or therapeutic outcome.Objective To identify microRNA expression patterns associated with colon adenocarcinomas, prognosis, or therapeutic outcome.Design, Setting, and Patients MicroRNA microarray expression profiling of tumors and paired nontumorous tissues was performed on a US test cohort of 84 patients with incident colon adenocarcinoma, recruited between 1993 and 2002. We evaluated associations with tumor status, TNM staging, survival prognosis, and response to adjuvant chemotherapy. Associations were validated in a second, independent Chinese cohort of 113 patients recruited between 1991 and 2000, using quantitative reverse transcription polymerase chain reaction assays. The final date of follow- up was December 31, 2005, for the Maryland cohort and August 16, 2004, for the Hong Kong cohort.Main Outcome Measures MicroRNAs that were differentially expressed in tumors and microRNA expression patterns associated with survival using cancer-specific death as the end point.Results Thirty- seven microRNAs were differentially expressed in tumors from the test cohort. Selected for validation were miR- 20a, miR- 21, miR- 106a, miR- 181b, and miR- 203, and all 5 were enriched in tumors from the validation cohort ( P